OneMedNet Reports Preliminary Revenue for Third Quarter 2026 and Fourth Quarter 2026 Outlook

OneMedNet posts 242% QoQ revenue growth, guiding for a tenfold Q4 surge.

What the company is saying

OneMedNet Corporation reports preliminary third quarter 2026 revenue of approximately $1 million, highlighting a 242% increase from the previous quarter and a 465% increase year-over-year. The company issues fourth quarter 2026 revenue guidance of $12 million to $14 million, contingent on customer acceptance of delivered data. Management attributes this acceleration to the scaling of its direct-from-source, multi-modal data platform and the completion of its de-identification pipeline and delivery infrastructure. CEO Aaron Green frames the technical and operational build-out as 'substantially complete,' positioning the company to convert its expanded sales funnel into revenue. The narrative emphasizes the company's network scale—over 2,300 sites, 90 million patient journeys, and 270 million studies—and its ability to deliver regulatory-grade, AI-ready datasets. The tone is confident, focusing on operational readiness and the expectation of rapid revenue recognition in Q4. The company notes that Q3 revenue aligns with previously communicated delivery timing and that results remain preliminary until the Form 10-Q release by November 16, 2026.

What the data suggests

The disclosed Q3 2026 revenue of approximately $1 million represents a dramatic sequential and year-over-year acceleration, with 242% growth over Q2 2026 and 465% over Q3 2025. The company’s Q4 2026 revenue guidance of $12 million to $14 million implies a near tenfold increase quarter-over-quarter, but this is explicitly dependent on customer acceptance of delivered data by year-end. The figures confirm top-line momentum but do not detail revenue composition, profitability, or cash flow. The company’s network spans more than 2,300 sites, 90 million patient journeys, and 270 million studies, supporting claims of scale but not directly substantiating the sales funnel or delivery assertions. The announcement lacks breakdowns of order backlog, customer concentration, or margin, so the sustainability and quality of revenue remain unassessed. The preliminary nature of Q3 results introduces a short-term risk of adjustment. Overall, the data supports a narrative of rapid growth but leaves key financial and operational questions unanswered.

Analysis

The announcement presents a highly positive tone, emphasizing dramatic sequential and year-over-year revenue growth and projecting a substantial increase in Q4 2026 revenue. While the Q3 2026 preliminary revenue figure ($1 million, +242% QoQ, +465% YoY) is a realised fact, the much larger Q4 2026 revenue guidance ($12–14 million) is forward-looking and contingent on customer acceptance, introducing uncertainty. Several claims about the sales funnel, scaled delivery, and completion of technical milestones are qualitative and lack supporting quantitative evidence. No profitability, margin, or cash flow metrics are disclosed, so the sustainability and value of the revenue growth cannot be assessed. The language around 'substantially complete' infrastructure and 'financial momentum' inflates the narrative beyond what is strictly evidenced by the numbers. However, the absence of a disclosed large capital outlay or acquisition means capital intensity is not flagged.

Risk flags

• ●The Q4 2026 revenue guidance of $12 million to $14 million is contingent on customer acceptance of delivered data, introducing execution risk if customers delay or reject acceptance, which could materially impact reported results.
• ●The announcement provides no detail on profitability, margin, or cash flow, so it is unclear whether rapid revenue growth translates into sustainable earnings or positive cash generation, raising questions about the underlying business quality.
• ●The preliminary Q3 revenue figure is subject to finalisation and adjustment before the official Form 10-Q release, so there is a risk that headline growth rates could be revised downward.
• ●Claims regarding the completion of technical infrastructure and the scaling of the sales funnel are qualitative and lack quantitative operational evidence, making it difficult to independently verify readiness for sustained high-volume delivery.

Bottom line

OneMedNet’s Q3 2026 revenue jump to $1 million signals a sharp acceleration, and the company is forecasting a massive Q4 leap to $12–14 million, pending customer acceptance. The top-line growth is real, but the Q4 outlook is highly contingent and not yet locked in. The company’s narrative is credible on network scale and technical build-out, but lacks transparency on profitability, cash flow, and the specifics of customer commitments. Investors should focus on the upcoming Form 10-Q for confirmation of Q3 results and watch for evidence that Q4 deliveries are accepted and converted to revenue. The most important takeaway is that while growth is accelerating, the sustainability and quality of this revenue remain to be proven.

Announcement summary

(NASDAQ:ONMD) OneMedNet Corporation announced preliminary revenue results for the third quarter ended September 30, 2026, and provided revenue guidance for the fourth quarter of 2026. The company expects to report revenue of approximately $1 million for the third quarter of 2026. This represents a 242% increase from the prior quarter ended June 30, 2026. It also represents a 465% increase from the prior-year quarter ended September 30, 2025. OneMedNet forecasts revenue of approximately $12 million to $14 million for the fourth quarter of 2026, pending anticipated acceptance of delivered data by customers. The company’s sales funnel has grown substantially over the course of 2026, and scaled delivery began during the third quarter of 2026. Revenue for 2026 is weighted to occur at a faster pace in the fourth quarter, consistent with order timing and scaled delivery. The company’s financial momentum is attributed to its First-Party (Direct-from-Source) multi-modal data sourced directly from healthcare provider partners and the scaling of its de-identified pipeline and delivery infrastructure. Aaron Green, President & CEO of OneMedNet, stated that the hardest work in the business—curating, de-identifying, and delivering regulatory-grade multimodal data at scale—is substantially complete, enabling the company to deliver its product to customers and convert sales to revenue. The anticipated revenue pace in the fourth quarter of 2026 is expected due to data coming direct from healthcare provider partners and the scaling of the de-identification pipeline and delivery infrastructure. Preliminary third quarter 2026 revenue is consistent with previously communicated delivery timing. The company’s network spans more than 2,300 sites. The network encompasses over 90 million patient journeys and 270 million studies. OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training. Third quarter 2026 revenue results are preliminary and subject to finalization and adjustment in connection with the preparation of the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which is expected to be released by November 16, 2026.

Disagree with this article?